DNA methylation changes between relapse and remission of minimal change nephrotic syndrome by Yasuko Kobayashi et al.
ORIGINAL ARTICLE
DNA methylation changes between relapse and remission
of minimal change nephrotic syndrome
Yasuko Kobayashi & Akira Aizawa & Takumi Takizawa &
Chikage Yoshizawa & Hiromi Horiguchi & Yuka Ikeuchi &
Satoko Kakegawa & Toshio Watanabe &
Kenichi Maruyama & Akihiro Morikawa &
Izuho Hatada & Hirokazu Arakawa
Received: 5 January 2012 /Revised: 31 May 2012 /Accepted: 11 June 2012 /Published online: 2 August 2012
# The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract
Background DNA methylation of gene promoters is associ-
ated with transcriptional inactivation. Changes in DNA
methylation can lead to differences in gene expression levels
and thereby influence disease development. We hypothe-
sized that epigenetics underlies the pathogenesis of minimal
change nephrotic syndrome (MCNS).
Methods Genome-wide DNA methylation changes between
relapse and remission in monocytes (n06) and naive T
helper cells (Th0s) (n04) isolated from patients with MCNS
were investigated using the microarray-based integrated anal-
ysis of methylation by isochizomers (MIAMI) method. We
confirmed the MIAMI results using bisulfite-pyrosequencing
analysis. Expression analysis was performed using quantita-
tive real-time PCR.
Results Three gene loci (GATA2, PBX4, and NYX) were
significantly less methylated in Th0s during relapse than
in remission, compared to none in monocytes. In addi-
tion, the distance distribution from the regression line of
all probes in MIAMI was significantly different between
monocytes and Th0s. The mRNA levels of the three
genes in Th0s were not significantly different between
relapse and remission.
Conclusions Our results demonstrate that the change in
DNA methylation patterns from remission to relapse in
MCNS occurs predominantly in Th0s rather than in mono-
cytes and suggest that epigenetic regulation in Th0s underlies
the pathogenesis of MCNS.
Keywords DNAmethylation . Nephrotic syndrome .
Monocytes . Naive T helper cells . Microarray-based
integratedanalysis ofmethylationby isoschizomers (MIAMI)
method . Genome-wide . Children
Introduction
Epigenetics is the study of mitotically heritable changes in
gene expression that occur without direct DNA sequence
alterations. DNA methylation, one of the principal epigenet-
ic mechanisms in mammals, involves the covalent addition
of a methyl group to a cytosine residue that is followed by a
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guanine (CpG) [1]. DNA methylation regulates gene expres-
sion and is essential for differentiation, embryonic develop-
ment [2], genomic imprinting [3], and X-chromosome
inactivation [4]. DNA methylation within the promoter re-
gion of a gene is commonly associated with transcriptional
inactivation, whereas demethylation contributes to tran-
scriptional activation. Changes in the DNA methylation
profile can also lead to differences in gene expression pat-
terns and thereby influence the development of diseases,
such as cancer [5].
Minimal change nephrotic syndrome (MCNS) is the
most common cause of nephrotic syndrome in children
and is characterized by massive proteinuria and hypoal-
buminemia in a relapse/remission course without histo-
logical evidence of immune-mediated inflammatory
damage. These manifestations are typically reversible
with the use of corticosteroid therapy. Although the
pathogenesis of MCNS remains to be elucidated, immu-
nological disruption has been implicated in this disease
[6] as T cell-derived vascular permeability factors have
been shown to be responsible for alterations in glomer-
ular permeability [7–9]. The incidence of MCNS in
childhood is twofold higher in boys, with a prevalence
that is inversely proportional to age, and recurrent re-
lapse tends to lessen after adolescence [10, 11]. Since the
characteristic features of MCNS include (1) a recurrent
relapse/remission course, (2) gender preference, (3) age
preference of onset and relapse, and (4) steroid response
in most patients, a genetic defect cannot explain the
pathogenesis of this disease; however, epigenetic alter-
ations may occur without a direct change in the genetic
sequence. DNA methylation changes with age and envi-
ronmental factors, even in the same individual, and is
involved with X-chromosome inactivation.
Audard et al. reported that NFRKB (nuclear factor related
to kappaB binding protein) was highly expressed in the
nuclear compartment during relapse and that NFRKB pro-
motes hypomethylation of genomic DNA, suggesting epi-
genetic involvement in the pathogenesis of MCNS [12]. The
epigenotype is influenced by the environment and alters the
regulation of gene expression, leading Elie et al. to suggest a
probable impact of epigenetic modifications in infected cells
since MCNS relapses are frequently triggered by external or
internal environmental factors, including viral infection
[13]. Zhang et al. reported significant differences in histone
H3 lysine 4 tri-methylation of peripheral blood mononuclear
cells (PBMCs) from adult patients with MCNS compared
with those from healthy subjects. Their results indicate that
alterations in epigenotype are associatedwith the pathogenesis
of MCNS [14].
The aim of this study is to elucidate whether the
DNA methylation profile changes between relapse and
remission in MCNS cases and whether this process is
immune-competent cell-type-specific. Ultimately, we




Samples for microarray-based integrated analysis of meth-
ylation by isochizomers (MIAMI) analysis were obtained
from six male patients with MCNS (Table 1), while samples
for quantitative real-time PCR (qRT-PCR) were obtained
from an additional seven patients with MCNS (3 boys, 4
girls) (Table 2) at relapse and also following complete
remission. All patients were diagnosed according to the
criteria of the International Study of Kidney Disease in
Children [15] and had developed nephrotic syndrome prior
to 16 years of age. Informed consent was obtained from the
parents of each child and from older children/adolescents as
necessary. This study was approved by the Ethics Commit-
tee of Gunma University Graduate School of Medicine,
Japan (Receipt Number 89).
Cell separation
We used monocytes, which are precursors of the antigen-
presenting cells derived from the myeloid cell series, and
naive T helper cells (Th0s), which are derived from the
lymphoid system, as material for the analyses. PBMCs were
isolated from 20-mL samples of anti-coagulated blood that
had been obtained by gradient separation using the Lymph-
prep™ Tube system (Axis-Shield PoC AS, Oslo, Norway).
Monocytes and Th0s were separated from PBMCs that had
been magnetically labeled with CD14, CD4, and CD45RO
microBeads (Miltenyi Biotec) using an autoMACS Pro Sep-
arator (Miltenyi Biotec, Bergisch Gladbach, Germany) . To
obtain monocytes, the CD14-positive (CD14+) fraction was
collected as monocytes, whereas the CD14-negative, CD4-
positive, and CD45RO-negative (CD14-CD4+CD45RO-)
fractions were collected as Th0s. Flow cytometric analysis
with a MACSQuant® Analyzer (Miltenyi Biotec) revealed
that the precision of cell separation was 96.2 % for CD14+
cells and 94.46 % for CD4-positive and CD45RA-positive
cells as a CD45RO-negative fraction.
CD14+ monocytes were obtained from six patients, while
CD14-CD4+CD45RO- Th0 cells were also obtained from
four of these patients (Table 1) for the MIAMI analysis both
at relapse and following complete remission. Genomic DNA
(gDNA) was extracted from these cells as previously de-
scribed [16]. Consistent amounts of extracted gDNA
(300 ng from monocytes and 250 ng from Th0s) from each
selected cell type were pooled and used for subsequent
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DNA methylation analysis using MIAMI in order to exclude
the influences of epigenetic differences among the cell
types, to identify specific changes due to clinical courses
of MCNS, and to reduce the noise caused by individual
differences. Total RNA was extracted from Th0s purified
from seven other patients with MCNS (Table 2) using a
ToTALLY RNA™ kit (Ambion, Austin, TX). Complemen-
tary DNA (cDNA) was synthesized from total RNA of each
Th0s sample using the High Capacity RNA-to-cDNA Mas-
ter Mix (Applied Biosystems, Foster City, CA) for the qRT-
PCR.
MIAMI analysis
The MIAMI method, which provides high-throughput global
analysis of DNA methylation, was performed as described
previously using 1.8 and 1.0 μg of pooled gDNA isolated
from the monocytes of six patients and from the Th0s of four
patients, respectively [17, 18]. Briefly, this technique utilizes
isoschizomers (HpaII and MspI) that recognize the same
recognition site (CCGG). Pooled gDNA was digested with
HpaII, a methylation-sensitive restriction enzyme that cleaves
only unmethylated DNA, and then adapter-ligated and ampli-
fied by PCR with primers designed against the adapter
sequences. The samples were then further digested withMspI,
a methylation-insensitive enzyme that digests CCGG sites
irrespective of their methylation status, and amplified again
with the same set of primers (HpaII–MspI treatment). The
second treatment with MspI yields amplicons from unmethy-
lated DNA fragments only. Hence, only HpaII cleavable
unmethylated DNA fragments are amplified, and these can
then be quantified based on their respective fluorescence
intensity by microarray analysis. The amplified products were
then labeled with Cy3 (remission samples) or Cy5 (relapse
samples) and co-hybridized to a microarray spotted with
38,172 sixty-mer oligonucleotides covering the vicinity of
the transcription start sites (TSSs) of 14,978 genes.
Following hybridization, the microarray was scanned, and
the obtained fluorescence intensities were quantified and nor-
malized. The same pooled gDNA samples were treated first
with MspI instead of HpaII (MspI–MspI treatment) and ana-
lyzed on a duplicate array to correct for false-positives caused
by single nucleotide polymorphisms or incomplete digestion.
Bisulfite-pyrosequencing analysis
In the bisulfite-pyrosequencing method, unmethylated cyto-
sine residues are converted into uracil, whereas methylated
cytosines remain unchanged. Analysis of the methylation
status in this manner exploits the quantitative nature of
pyrosequencing by reporting the ratio of cytosine to thymine
at each analyzed CpG site, which reflects the proportion of
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samples in accordance with established protocols. Briefly,
gDNA extracts from patients were digested with EcoRI
(Takara Bio, Otsu, Japan) and subjected to bisulfite treatment
using the EZ DNA Methylation-Gold Kit (Zymo Research,
Orange, CA). The analyzed CpG sites were in the closest
HpaII recognition sites at the 5′- and 3′- ends of the probes
designed in the TSSs vicinity of GATA2 (A_17_P02574948),
PBX4 (A_17_P10909964), and NYX (A_17_P11717994)
used in the MIAMI analysis. Amplification and sequencing
primers for pyrosequencing were designed with PyroMark
Assay Design software ver. 2.0 (Qiagen, Venlo, the Nether-
lands) (Electronic Supplementary Material Table 1).
The targeted DNA segments were amplified using a hot
start protocol with a touchdown PCR system (Veriti™ Ther-
mal Cycler; Applied Biosystems), and the strand serving as
the pyrosequencing template was biotinylated. Following de-
naturation, the biotinylated single-stranded PCR amplicons
were isolated and allowed to hybridize with a sequencing
primer. Pyrosequencing (PyroMark Gold Q96 Reagents; Qia-
gen) was then performed using the PyroMark Q24 system
(Qiagen) according to the manufacturer’s protocol. The se-
quencing assay was validated using an internal control (a non-
CpG cytosine within the target methylation sequence region).
Quantitative real-time PCR
The qRT-PCR analysis was performed using the TaqMan
PCR method with a 7900HT Fast Real-Time PCR System
(Applied Biosystems) with cDNA from Th0s separated
from the other patients with MCNS at relapse and subse-
quent remission. The three genes previously analyzed using
MIAMI, namely, GATA2 (Hs00231119_m1), PBX4
(Hs00257935_m1), and NYX (Hs00360869_m1), were
assayed. Each gene was assayed four times for each sample.
Aliquots of cDNA equivalent to 300 ng of total RNA were
used in the RT-PCR reactions. GAPDH (Hs99999905_m1)
was used as an endogenous control for normalizing the RNA
concentrations. Differences in the CT values between the
tested genes and endogenous control (ΔCT) were calculated
and used for subsequent statistical analyses.
Statistical analysis
Statistical analyses of the distance distributions from the
MIAMI regression line for each of the probes used in the
assays was performed using a non-parametric Mann–Whit-
ney U test (Fig. 1). Comparisons between the expression
levels for each group were analyzed using the Wilcoxon
matched-pairs signed-rank test (Fig. 4a, b). All statistical
analyses were performed using GraphPad PRISM5 software
(GraphPad Software, La Jolla, CA) with the significance
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Results
Patients for DNA methylation analysis
We first investigated whether any genome-wide changes in
DNA methylation occurred between relapse and remission
in the patients with MCNS. The mean total follow-up period
until June 2011 was 109.5 months (range 35–188 months).
All patients were steroid responsive and frequent relapsers
within their total clinical course. Renal biopsy was per-
formed during the follow-up period in four patients who
had been administered cyclosporine because of their fre-
quent relapses in order to histologically evaluate the side
effects of cyclosporine. The histological findings were con-
sistent with the diagnosis of MCNS. The ages at sampling
for relapse and the total number of relapses until samples
were collected are listed in Tables 1 and 2. The mean age at






























Fig. 1 a, b Scatter plots of the signals obtained for each probe in
monocytes (a) and naive T helper cells (b). Log [(HpaII intensity)
Remission/(HpaII intensity) Relapse] values are plotted on the x-axis
and log[(MspI intensity) Remission/(MspI intensity) Relapse] values
are plotted on the y-axis. The threshold values are determined at log5 of
the horizontal distance from the center of the mass and at log5 of the
horizontal distance to the regression line of the plots in accordance
with the original MIAMI method of Hatada et al. [17, 18]. Points
located on the right side and beyond the distance of these lines are
judged to be more highly methylated; those located to the left are
judged to be significantly less methylated in the relapse samples
compared with the remission samples. The three gene probes were
found to be less methylated in relapse samples than in remission
samples in naive T helper cells (b), whereas no significant signal was
detected in monocytes (a). c Distance distributions of all probes are
from the regression line. Each dot indicates the log distance of the
indicated probes plotted out to the 90th percentile of signals from the
regression line. These distributions were significantly different (P0
0.0073) between monocytes and naive T helper cells (Th0s)
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19 years and 10 months), and the mean number of relapses
at the time of sampling was six (range 3–13 relapses). The
mean sampling interval from the relapse to the subsequent
remission was 25 (range 5–71) weeks. The therapeutic con-
ditions were similar at the time of relapse and remission
sampling in all subjects except for patients 2 and 6, who
received a corticosteroid (patients 2 and 6) and immunosup-
pressant (patient 2) at remission (Tables 1, 2).
MIAMI analysis
The scatter plots of the signals from each probe in mono-
cytes and Th0s are shown in Fig. 1a and b. The values for
log [(HpaII intensity) remission/(HpaII intensity) relapse]
are plotted on the x-axis, which represents the relative
methylation changes upon relapse compared with those at
remission. The values for the log [(MspI intensity) remis-
sion/(MspI intensity) relapse] are plotted on the y-axis and
represent the control of the enzyme effects at sample diges-
tion. The threshold values were determined according to the
original MIAMI method described by Hatada et al [17, 18].
Three probes were found to be less methylated in the relapse
Th0s samples compared with those taken at remission,
whereas none of the probes had a significant detectable
signal in monocytes (Fig. 1a and b). The distance distribu-
tions of all probes from the regression line were significant-
ly different (P00.0073) between monocytes and Th0s














Fig. 2 Gene maps of GATA2 (a), PBX4 (b), and NYX (c), including the
position of the probes used in the MIAMI analysis. The number of
CpG (covalent addition of a methyl group to a cytosine residue fol-
lowed by a guanine) islands and the CG percentages throughout the
genomic regions of these genes are also indicated. GATA binding
protein 2 (GATA2) maps to chromosome (Ch) 3 q21.3, pre-B-cell
leukemia homeobox 4 (PBX4) maps to Ch19 p12, and nyctalopin
(NYX) maps to Ch X p11.4. Filled squares indicate the position of
the probes with significant changes to the methylation status in Th0s.
Probe A_17_P02574948 for GATA2 recognizes the region 3.6 kb up-
stream of the transcription start site of this gene, which is within a CpG
island. The probe A_17_P10909964 sequence in PBX4 is located
within the first intron of this gene, and probe A_17_P11717994 for
NYX maps to the region just upstream of the transcription start site
Table 3 Signal intensity ratio in HpaII-treated samples for the indicated gene probes
Cell type Gene Probe Aa Assessedb
Naive T cells GATA2 A_17_P02574948 0.167722527 −1
PBX4 A_17_P10909964 0.174326395 −1
NYX A_17_P11717994 0.151913072 −1
Monocytes GATA2 A_17_P02574948 2.523381325 0
a Signal intensity ratio calculated by [(HpaII intensity) Remission/(HpaII intensity) Relapse] indicating an unmethylated intensity ratio for
remission vs. relapse
b −1, Signal intensity ratio at this probe is located further left than the threshold lines indicating significantly lower methylation in the relapse
samples than in the remission samples; 0, signal intensity ratio at this probe is located within the threshold lines
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status undergoes changes between relapse and remission in
Th0s from MCNS patients and that the regulation of
DNA methylation differs between monocytes and Th0s.
The three genes detected in Th0s were GATA binding
protein 2 (GATA2) at chromosome (Ch) 3 q21.3, pre-B-cell
leukemia homeobox 4 (PBX4) at Ch 19 p12, and nyctalopin
(NYX) at Ch X p11.4. The locations of the probes used to
detect these three genes are shown in Fig. 2. The remission-
to-relapse signal intensity ratios measured by MIAMI for
the three probes following HpaII treatment are shown in
Table 3 and indicate the unmethylated intensity ratio between
relapse and remission.
Bisulfite-pyrosequencing analysis
To confirm the results of the MIAMI analysis, we directly
analyzed the methylation ratio using bisulfite-pyrosequencing
for the CpGs that were in the closest CCGGHpaII recognition
sites on either side of the recognition sequences of all 3 probes
tested inMIAMI analysis (Fig. 3a). At all sites in this analysis,
the methylation ratios in Th0s were found to be lower at
relapse than in remission (Fig. 3b). The methylation ratios
for the GATA2 probe A_17_P02574948 in monocytes were
also tested and found to be higher at relapse than in remission
on both sides of the probe (Fig. 3c). The methylation status at
every CpG site determined by bisulfite-pyrosequencing
analysis accorded well with the earlier MIAMI data (Table 3).
qRT-PCR analysis
According to the MIAMI analysis results, expression of the
3 genes under examination was determined in Th0s from the
other patients with MCNS (Table 2) at relapse and subse-
quent remission using qRT-PCR (Fig. 4). GATA2 expression
was low and did not change significantly between relapse
and remission (P00.0781; Fig. 4a). PBX4 expression was
also detectable but did not change significantly (P00. 2188;




Fig. 3 DNA methylation ratio analysis by bisulfite-pyrosequencing. To
validate the MIAMI data, methylation ratios for CpGs in the closest CCGG
HpaII recognition sites on both the 5′ (UP) and 3′ (DN) side of the probe
sequences were determined using bisulfite-pyrosequencing (a). These ratios
were lower in minimal change nephrotic syndrome (MCNS) relapse (Rel)
samples than in remission (Rem) samples at all sites for the three probes in
Th0s (b). The methylation ratios for theGATA2 probe A_17_P02574948 in
monocytes (c) were higher in Rel than in Rem at both sides of the probe.
The methylation pattern at every CpG site determined using bisulfite-
pyrosequencing accorded well with the MIAMI results (Table 3), which
indicate an unmethylated intensity ratio between relapse and remission
a b
Fig. 4 Expression of GATA2 and PBX4 genes in Th0s from patients
with minimal change nephrotic syndrome at relapse and in remission.
Nyctalopin (NYX) was not detected in Th0s. a GATA2 expression was
low and did not change significantly (P00.0781) between relapse and
remission. b PBX4 expression did not differ significantly (P00. 2188)
between relapse and remission
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Discussion
A number of different approaches have been adopted in
attempts to elucidate the mechanisms underlying alterations
in the glomerular capillary permeability in MCNS. These
have included studies of the capillary loop membrane, in-
cluding the podocytes [19–23], searches for secretory fac-
tors which may change the permeability of the membrane
[4, 24, 25], and investigations of immunocytes as a source
of these factors [26, 27]. In the study reported here, we
focused on immunocytes and their epigenetic regulation.
We specifically isolated and studied Th0s and monocytes
rather than using PBMCs, which usually include a wide
range of cell types at different differentiation stages, as the
latter cells would likely have a distinct epigenotype that
could change even through the normal differentiation of
Th0s to T helper cells, subset 2 (Th2) [28, 29]. We targeted
naive or precursor cells in our search for possible predis-
posing causes of MCNS to exclude other influences on
disease activity, such as Th2 activation, which has been
reported in MCNS [30–33].
Differences in epigenetic patterns have been reported to
occur even in genetically identical twins, which may be due
to the influence of environmental factors [34]. In our experi-
ments, it was possible to eliminate the effects of environmental
or aging factors, which can impact on epigenotype variation
among individual subjects, by comparing the DNA methyla-
tion differences in samples from the same individual obtained
within short intervals (Tables 1, 2). However, it was impossible
to exclude the effects of treatment with corticosteroids and
cyclosporine A, which one and four patients received, respec-
tively, although we could not find clear evidence of the impact
of those medicines on the regulation of DNA methylation in
immunocytes.
GATA2 is a member of the GATA family of zinc-finger
transcription factors (TFs), which play an essential role in the
hematopoietic and endocrine systems (http://www.ncbi.nlm.
nih.gov/pubmed?term0gata2). PBX4 is a homeodomain pro-
tein similar to a TF that is involved in translocations in pre-B-
cell leukemia (http://www.ncbi.nlm.nih.gov/pubmed?
term0PBX4). NYX is a member of the small leucine-rich
proteoglycan family of proteins in which defects can cause
congenital stationary night blindness type 1, a rare inherited
retinal disorder (http://www.ncbi.nlm.nih.gov/pubmed?
term0nyx). Our finding that the DNA methylation ratios were
lower in MCNS relapse samples within the promoter regions
of these genes suggests that their expression might be higher
at relapse than in remission. However, the expression of
GATA2 and PBX4 were not higher at relapse in Th0s. One
possible explanation for this result is that these two genes are
in a primed state for transcription but are not necessarily
activated in naive T cells. Changes in DNA methylation may
precede changes in gene expression and influence the
differentiation of Th0s into effector Th cells and/or influence
gene expression after differentiation, which in turn affects the
immunological and clinical states of MCNS.
Our findings that DNA methylation levels differ between
the tested cell types—one from the myeloid series of cells and
the other from the lymphoid system—indicates that it is
necessary to separate the different types of immunocytes to
investigate the epigenetic regulation of associated diseases,
even though they are included in the general PBMC popula-
tion. Although further analysis is required to determine can-
didate genes for MCNS, we conclude from our results data
that the regulation of DNA methylation in Th0s, but not in
monocytes, differs significantly between relapse and remis-
sion in affected patients and that epigenetic regulation in Th0s
underlies the pathogenesis of MCNS, whose disturbances
have been implicated in the development of the disease.
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